As an example, approximately 71% of Asiatic patients with PPA harbored EGFR mutation [26] and EGFR‐TKIs was used to lengthen progression‐ free survival in patients with an EGFR gene mutation and was introduced as first‐line therapy in these patients [27]. Here, EGFR is linked to primary progressive aphasia.